EpiTET's novel targets and molecular glue degrader approach has the potential to revolutionize the way we treat a number of chronic inflammatory conditions including endometriosis, metabolic dysfunction (MASH), cancers, and other conditions. Our approach selectively eliminates pathogenic macrophages, the key drivers of chronic inflammation and disease micro-environment without suppressing overall immunity.
Company Details
- Employees
- 4
- Founded
- 2024
- Address
- New Haven, Connecticut, Us
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- HQ
- New Haven, Connecticut
Epitet Therapeutics Questions
Epitet Therapeutics's LinkedIn profile is https://www.linkedin.com/company/epitet-therapeutics
Epitet Therapeutics has
4 employees.
View email and phone details for 4
employees at Epitet Therapeutics.
Epitet Therapeutics's industry is
Biotechnology Research
Epitet Therapeutics's top competitors are
Renetx Bio,
Foresite Capital,
Hybridex Biosciences,
Partnology,
Psymed Ventures,
Nephrogen,
Cloverleaf Bio,
Brightedge - American Cancer Society,
Arvinas,
Canaan.
Epitet Therapeutics's categories are Biotechnology Research
Epitet Therapeutics's founding year is 2024
